You are here
OvaScience Ringing NASDAQ Bell
a blog by Jennifer A. Redmond, September 5, 2013
Michelle Dipp, M.D., Ph.D., CEO of OvaScience is ringing the NASDAQ Stock Market Opening Bell this morning. OvaScience has patented technologies that intend to advance infertility treatment. OvaTureSM seeks to create mature fertilizable eggs from a woman’s own egg precursor cells without the need for hormone injections, and AUGMENTSM aims to improve egg quality and increase IVF success.
“Ringing the NASDAQ opening bell is a milestone for OvaScience and recognizes the tremendous dedication of our team of scientists, clinicians, advisors and advocacy partners who share our mission to make new treatment options available to the millions of couples throughout the world struggling with infertility,” Dipp says.
OvaScience is the second infertility-focused organization to ring the NASDAQ Opening Bell in the last 30 days. Baby Quest Foundation did so on August 13, 2013.
With one in six U.S. couples afflicted with infertility, let’s hope this type of attention generates conversation and awareness about the disease.